Ehsan Ghayoor Karimiani - Molecular Diagnostic Unit, Research and Education Department, Razavi Hospital, Mashhad, IR Iran
Abolghasem Allahyari - Hematology Oncology Department, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran

Context: Chronic myeloid leukemia (CML) is believed to occur following the clonal expansion of haematopoietic stem cells and ismaintained by expanding clones which have acquired a BCR-ABL fusion gene. The properties of untreated CML stem/progenitor cellscorrelate with a subsequent response to chemotherapy. Evidence Acquisition: The fifty two significant articles discussing the stem cell in chronic myeloid leukemia from 1996 to 2012 wereselected according to the authors’ experience. Results: Studies have shown that primitive CML cells are less responsive to Tyrosine Kinase Inhibitors (TKIs) and are a reservoir for therelapse of multi drug resistant (MDR). Conclusions: Following that, minimal residual disease (MRD) measurement aims to detect very small numbers of leukemic cells, belowthe detection limit of morphology and cytogenetics with molecular techniques for patients in clinical remission.

Chronic Myeloid Leukemia; Progenitor Cell; Protein Kinase Inhibitors; Stem Cell